Skip to content

Study · Not a test of the peptide alone · 2021

2 results

Intra-arterial infusion of autologous bone marrow mononuclear cells combined with intravenous injection of cerebrolysin in the treatment of middle cerebral artery ischemic stroke: Case report.

Le VC, Nguyen NH, Le SH

SAGE open medical case reports17 Mar 2021Cited by 2 (Europe PMC)

PMID33796315 (opens in a new tab)PMCIDPMC7975445 (opens in a new tab)DOI10.1177/2050313x211002313 (opens in a new tab)PepBankPUB-33796315
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a patient with severe middle cerebral artery occlusion, intra-arterial bone marrow cells combined with Cerebrolysin were followed by functional and neurological improvements, especially functional motor recovery.

    In plain wordsIn one stroke patient, bone marrow cells with Cerebrolysin were followed by functional and neurological improvement, especially in movement.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional and neurological improvement, especially functional motor recovery
    Study

    n = 1

    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    After the therapy, the patient showed good outcome with functional as well as neurological improvements especially in terms of functional motor recovery without any side effects.
    1 context sentence
    Summary · context
    We present a patient with severe middle cerebral artery occlusion who received an intra-arterial infusion of autologous bone marrow stem cells combined with Cerebrolysin IV.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02HumanNot a test of Cerebrolysin aloneCase report or seriesSafety outcome

    In a patient with severe middle cerebral artery occlusion, no side effects occurred after bone marrow cells combined with Cerebrolysin.

    In plain wordsIn a stroke patient, no side effects occurred after bone marrow cells with Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSide effects
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    After the therapy, the patient showed good outcome with functional as well as neurological improvements especially in terms of functional motor recovery without any side effects.
    1 context sentence
    Summary · context
    We present a patient with severe middle cerebral artery occlusion who received an intra-arterial infusion of autologous bone marrow stem cells combined with Cerebrolysin IV.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.